Prescription Drug Monitoring Programs

Prescription Drug Monitoring Programs (PDMP/PMPs) are critical decision support tools that state officials, health care professionals, and law enforcement officers use to address opioid and prescription drug abuse and diversion. PDMP/PMPs electronically collect, analyze and disclose specified information about prescribed controlled substances and other monitored substances dispensed to patients and their representatives.

Search for any of NAMSDL’s PDMP/PMP materials

Document Selector

 

 

Type of Document
Sub-Topic of Document

 

Source of Document

Results

 

January 2017
One-page flyer on prescription drug monitoring program (PDMP/PMP) basics
Annual Review PDMP - The review includes relevant information on the changes made in the past year in certain areas related to PMPs, such as mandatory registration and access, types of authorized users, etc., and includes a map of the current status of states within that category.
Press Release on ASAP Updates 4.2 of the PDMP Reporting Standard with the Release of 4.2A by the American Society for Automation in Pharmacy
This issue of NAMSDL Case Law Update focuses on seven cases related to the access to and use of prescription monitoring program (“PMP”) records. The issues addressed in these decisions involve: (1) the preemption of state law by the administrative subpoena provisions of the Controlled Substances Act (“CSA”) (21 U.S.C. § 876); (2) privacy rights implicated by accessing PMP records; and (3) whether or not certain login information constitutes protected PMP information. The cases discussed in this issue originate from California, Louisiana, Mississippi, Oregon, Utah, and Virginia. Cases are divided by type of court (federal or state) and then listed in approximate descending order of appellate level.
Report idntifying the components of a strong prescription drug monitoring program
Map of Evaluation of PMP – Report To Legislature. As part of the evaluation process, some states require that the prescription monitoring program, or the advisory committee for the program, make a report to the legislature regarding the effectiveness of the program, typically on an annual basis. Effectiveness measures include a reduction in the inappropriate use of controlled substances and a reduction in the ability of consumers to obtain controlled substances illegally.
Report on Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule and prescription drug monitoring programs (PDMPs/PMPs). Since 2004, NAMSDL has helped state and federal officials assess the applicability of state and federal confidentiality and privacy laws, regulations and rules to the interstate disclosure of dispensed substances information. A primary focus has been the potential impact of the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule (Privacy Rule). 45 C.F.R. Part 160 and Subparts A and E of Part 164.
HIPAA summary of key provisions
Report released by the CDC on Integrating and Expanding Prescription Drug Monitoring Program Data: Lessons From Nine States
50 state compilation of ASAP Version Used

 

Notice of Federal Funding Disclaimer

 This website is funded in part through a cooperative agreement from the Bureau of Justice Assistance, Office of Justice Programs, U.S. Department of Justice and a grant from the Office of National Drug Control Policy. No federal instrumentality, including the Office of Drug Control Policy, the U.S. Department of Justice or its components, operate, control, are responsible for or necessarily endorse this website (including, without limitation, its content, technical infrastructure, policies and any services or tools provided).